In conclusion, short-term exposure to lapatinib during the premalignant risk window for developing erbB-2-overexpressing mammary tumors resulted in a striking shift in tumor onset, which was preceded by delayed mammary morphogenesis and inhibition of molecular signaling pathways that regulate cell proliferation, cell survival, and stem cell self-renewal. The gene discussed is ERBB2; the disease is neoplasm.